Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-MTAB-9767

ABSTRACT: RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC)

PROVIDER: E-MTAB-9767 | ExpressionAtlas | 2025-01-23

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-MTAB-9767-analysis-methods.tsv	Tabular
	E-MTAB-9767-analytics.tsv	Tabular
	E-MTAB-9767-atlasExperimentSummary.Rdata	Rdata
	E-MTAB-9767-configuration.xml	Xml
	E-MTAB-9767-g2_g1-mvaPlot.png	Other

Items per page:

1 - 5 of 20

Similar Datasets

RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC)

Project description:RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC)

| PRJEB41364 | ENA

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (RNA-Seq Neutrophils)

Project description:Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (RNA-Seq Neutrophils)

| PRJNA630915 | ENA

RNA-seq of human multiple myeloma patients myeloid-derived suppressor cells (M-MDSC)

Project description:The aim of this study is to evaluate prognostic impact of M-MDSCs (Myeloid-derived suppressor cells) in multiple myeloma (MM) remains in the context to autologous stem cell transplantation (ASCT).

2020-11-26 | E-MTAB-9767 | biostudies-arrayexpress

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (RNA-Seq Epigenetic treatments)

Project description:Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (RNA-Seq Epigenetic treatments)

| PRJNA630913 | ENA

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (RNA-Seq Neutrophils TGFbeta)

Project description:Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (RNA-Seq Neutrophils TGFbeta)

| PRJNA630912 | ENA

Transcription profiling by microarray of High-density neutrophils in multiple myeloma and monoclonal gammopathy patients compared to healthy donors.

Project description:Multiple Myeloma (MM) is a plasma cell malignancy with a well- documented immune dysfunction. We previously showed that granulocyte-myeloid derived suppressor cells (G-MDSC) are increased in MM thus to contribute to refractoriness to lenalidomide. MM-, differently from MGUS, mesenchymal cells lead myeloid precursors to acquire G-MDSC phenotype, suggesting that MM-microenvironment can affect myeloid maturation. Because there is a phenotypic overlapping between G-MDSC and mature high-density neutrophils (HDN), we investigated functionally HDN to gauge their contribution in immune-suppression in patients affected by monoclonal gammopathy of uncertain significance (MGUS) and symptomatic MM.

2020-01-20 | E-MTAB-6105 | biostudies-arrayexpress

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma

Project description:Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma

| PRJNA630901 | ENA

Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (ATAC-Seq Neutrophils)

Project description:Immunogenomic identification and characterization of granulocytic myeloid derived suppressor cells in multiple myeloma (ATAC-Seq Neutrophils)

| PRJNA630897 | ENA

Inhibition of the Aryl Hydrocarbon Receptor - Polyamine Biosynthesis Axis Suppresses Multiple Myeloma and prostate cancer progression

Project description:Polyamine inhibition for cancer therapy is, conceptually, an attractive approach but has yet to meet success in the clinical setting. The aryl hydrocarbon receptor (AHR) is the central transcriptional regulator of xenobiotic response. Our study revealed that AHR also positively regulated intracellular polyamine production via direct transcriptional activation of two genes (ODC1 and AZIN1) involved in polyamine biosynthesis and control, respectively. In multiple myeloma patients, AHR levels inversely correlated with survival, suggesting that AHR inhibition may be beneficial for treatment of this disease .We identified clofazimine, an FDA-approved anti-leprosy drug, as a potent AHR antagonist and a suppressor of polyamine biosynthesis. Experiments in a transgenic model of multiple myeloma (Vk*Myc mice) and in immunocompromised mice bearing multiple myeloma cell xenografts, revealed high efficacy of clofazimine comparable to that of bortezomib, a first-in-class proteasome inhibitor used for treatment of multiple myeloma. This study identified a previously unrecognized regulatory axis between AHR and polyamine metabolism and discovered clofazimine as an inhibitor of AHR and a potentially clinically-relevant anti-multiple myeloma agent. RNA-seq: human multiple myeloma MM1S and human normal fibroblasts WI38 cells -/+ CLF 2-4uM for 24hrs; -/+ shAHR

2018-07-18 | GSE117160 | GEO

Homo sapiens

Project description:RNA-seq of LAMP5 in human multiple myeloma cells

| PRJNA1160438 | ENA